RUXOLITINIB for Haematological malignancy: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 35 adverse event reports in the FDA FAERS database where RUXOLITINIB was used for Haematological malignancy.
Most Reported Side Effects for RUXOLITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 12,492 | 18.3% | 1,527 | 1,769 |
| Death | 6,561 | 9.6% | 6,541 | 687 |
| Fatigue | 5,663 | 8.3% | 280 | 1,124 |
| Anaemia | 3,593 | 5.3% | 539 | 1,438 |
| Haemoglobin decreased | 3,297 | 4.8% | 456 | 1,306 |
| Platelet count decreased | 3,028 | 4.4% | 540 | 1,198 |
| Diarrhoea | 2,531 | 3.7% | 193 | 827 |
| Asthenia | 2,529 | 3.7% | 305 | 949 |
| Dizziness | 2,398 | 3.5% | 102 | 587 |
| Pneumonia | 2,343 | 3.4% | 643 | 1,726 |
| Headache | 2,271 | 3.3% | 97 | 541 |
| Product availability issue | 2,142 | 3.1% | 20 | 188 |
| Product dose omission issue | 2,130 | 3.1% | 41 | 281 |
| Dyspnoea | 2,042 | 3.0% | 258 | 886 |
| Splenomegaly | 1,995 | 2.9% | 292 | 686 |
Other Indications for RUXOLITINIB
Myelofibrosis (21,650)
Polycythaemia vera (12,352)
Myeloproliferative neoplasm (2,982)
Product used for unknown indication (2,869)
Graft versus host disease (2,291)
Primary myelofibrosis (2,234)
Essential thrombocythaemia (1,788)
Chronic graft versus host disease (1,679)
Acute lymphocytic leukaemia (1,105)
Vitiligo (1,053)
Other Drugs Used for Haematological malignancy
RITUXIMAB (144)
CYCLOPHOSPHAMIDE (97)
FLUDARABINE (93)
BUSULFAN (80)
LENALIDOMIDE (71)
IBRUTINIB (62)
DOXORUBICIN (61)
BEVACIZUMAB (55)
GENOXAL INYECTABLE (49)
MYCOPHENOLATE (49)